Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events (Q33813213)

29 July 2017

1 reference

title

Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events (English)

1 reference

29 July 2017

J W Freston

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

American Journal of Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

107

1 reference

29 July 2017

issue

6A

1 reference

29 July 2017

page(s)

78S-88S; discussion 89S

1 reference

Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Pharmacology and efficacy of cyclooxygenase (COX) inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

General tolerability and use of nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear str

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Expression of the cyclooxygenase-2 gene in gastric epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Cyclooxygenase 2 and wound healing in the stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Gastrointestinal safety profile of nabumetone: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

A Look at the Rule of Three

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Safety profiles of leading nonsteroidal anti-inflammatory drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900371-X

10.1016/S0002-9343(99)00371-X

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference